ProMIS Neurosciences Identifies Third Novel Therapeutic Target for Alzheimer's Disease Biotech Investing
Galapagos Reports Results from 10-week Analysis of Phase 2 Study with Filgotinib in Crohn's Disease Biotech Investing
Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression Biotech Investing
Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation for DTX301 for the Treatment of Ornithine Transcarbamylase Deficiency Biotech Investing
Naturally Splendid Announce Lotte Home Shopping Channel Launches NATERA in South Korea Biotech Investing
KemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP Biotech Investing
